Literature DB >> 2655161

Effects of an antithrombotic agent (MD-805) on progressing cerebral thrombosis.

S Kobayashi1, M Kitani, S Yamaguchi, T Suzuki, K Okada, T Tsunematsu.   

Abstract

The effects of the newly developed synthetic selective antithrombin agent MD-805 were examined in 11 patients with progressing cerebral thrombosis, as an open trial. Nine (82%) of 11 patients improved after 1 week of intravenous drip infusion. No hemorrhagic complications were observed during the therapy. These results suggest that MD-805 is a safe and effective agent for treatment of progressing cerebral thrombosis.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2655161     DOI： 10.1016/0049-3848(89)90105-9

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


  4 in total

Review 1.  A synopsis of the clinical uses of argatroban.

Authors:  M Moledina; M Chakir; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

2.  Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: placebo-controlled study.

Authors:  Y Ueki; K Matsumoto; Y Kizaki; K Yoshida; Y Matsunaga; M Yano; S Miyake; Y Tominaga; K Eguchi
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

3.  Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.

Authors:  D J Fitzgerald; G A Fitzgerald
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

4.  Treatment for Patients with Acute Ischemic Stroke Presenting beyond Six Hours of Ischemic Symptom Onset : Effectiveness of Intravenous Direct Thrombin Inhibitor, Argatroban.

Authors:  Jung Soo Park; Seung Soo Park; Eun Jeong Koh; Jong Pil Eun; Ha Young Choi
Journal:  J Korean Neurosurg Soc       Date:  2010-04-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.